Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol 3-kinase beta (PI3Kβ) is a class IA PI3K that functions as an obligate heterodimer composed of a p110β catalytic subunit and a regulatory subunit (commonly p85, but also p55 or p50). It catalyzes the phosphorylation of phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P₂] to generate phosphatidylinositol-(3,4,5)-trisphosphate [PI(3,4,5)P₃], a key lipid second messenger. Unlike other class I isoforms, PI3Kβ can be activated by both RTKs and GPCRs, and it also interacts with small GTPases like Rac1(GTP). It plays a role in cell metabolism, survival, proliferation, and motility, and is especially important in spermatogenesis, macrophage function, osteoclast development/function, neutrophil activity, and platelet activation/thrombosis regulation. It is implicated in cancer progression, especially PTEN-deficient tumors.
PI3Kβ inhibitors
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol 3-kinase beta subunit (PI3Kβ).